Adicet Bio, Inc. (0HX7.L)
0HX7.L Stock Price Chart
Explore Adicet Bio, Inc. interactive price chart. Choose custom timeframes to analyze 0HX7.L price movements and trends.
0HX7.L Company Profile
Discover essential business fundamentals and corporate details for Adicet Bio, Inc. (0HX7.L) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Pharmaceuticals
IPO Date
8 Jan 2021
Employees
152.00
Website
https://www.adicetbio.comCEO
Chen Schor BA, CPA,
Description
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.
0HX7.L Financial Timeline
Browse a chronological timeline of Adicet Bio, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 4 May 2026
Upcoming earnings on 4 Mar 2026
Upcoming earnings on 4 Nov 2025
Upcoming earnings on 11 Aug 2025
Earnings released on 6 May 2025
EPS came in at -$0.31 surpassing the estimated -$0.33 by +6.53%.
Earnings released on 6 Mar 2025
EPS came in at -$0.32 surpassing the estimated -$0.36 by +11.34%.
Earnings released on 7 Nov 2024
EPS came in at -$0.34 surpassing the estimated -$0.34 by +0.15%.
Earnings released on 13 Aug 2024
EPS came in at -$0.33 surpassing the estimated -$0.36 by +9.33%.
Earnings released on 15 May 2024
EPS came in at -$0.35 surpassing the estimated -$0.45 by +21.00%.
Earnings released on 20 Mar 2024
EPS came in at -$0.69 surpassing the estimated -$0.70 by +1.64%.
Earnings released on 9 Nov 2023
EPS came in at -$1.16 falling short of the estimated -$0.74 by -57.48%.
Earnings released on 10 Aug 2023
EPS came in at -$0.75 falling short of the estimated -$0.46 by -63.98%.
Earnings released on 10 May 2023
EPS came in at -$0.72 falling short of the estimated -$0.58 by -24.75%.
Earnings released on 16 Mar 2023
EPS came in at -$0.72 falling short of the estimated -$0.28 by -156.16%.
Earnings released on 30 Sept 2022
EPS came in at -$0.53 surpassing the estimated -$0.53 by +0.68%.
Earnings released on 30 Jun 2022
EPS came in at -$0.56 falling short of the estimated -$0.46 by -23.60%.
Earnings released on 31 Mar 2022
EPS came in at $0.10 surpassing the estimated -$0.18 by +155.22%, while revenue for the quarter reached $24.99M, beating expectations by +73.64%.
Dividend declared on 15 Mar 2022
A dividend of $0.29 per share was announced, adjusted to $0.29.
Earnings released on 31 Dec 2021
EPS came in at -$0.47, while revenue for the quarter reached $5.47M.
Earnings released on 30 Sept 2021
EPS came in at -$0.44 falling short of the estimated -$0.42 by -4.36%, while revenue for the quarter reached $3.43M, missing expectations by -17.66%.
Earnings released on 30 Jun 2021
EPS came in at -$0.34, while revenue for the quarter reached $4.81M.
Earnings released on 31 Mar 2021
EPS came in at -$0.82, while revenue for the quarter reached -$3.98M.
Stock split effective on 8 Jan 2021
Shares were split 1:7, changing the number of shares outstanding and the price per share accordingly.
Earnings released on 31 Dec 2020
EPS came in at -$0.46, while revenue for the quarter reached $5.41M.
Earnings released on 30 Sept 2020
EPS came in at -$2.84, while revenue for the quarter reached $3.03M.
0HX7.L Stock Performance
Access detailed 0HX7.L performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.